Please login to the form below

Not currently logged in
Email:
Password:

Idera

This page shows the latest Idera news and features for those working in and with pharma, biotech and healthcare.

Big pharma and biotech M&A activity increases in Q4 2006

530. Idera. Merck. Toll-like Receptor (TLR) agonists. 455. AC Immune. Genentech.

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    There are various companies working on toll-like receptor agonists that stimulate antigen-presenting cells, such as Idera’s TLR9-targeted drug IMO-2125 which boosted the activity of BMS’CTLA4

  • Deal Watch November 2016 Deal Watch November 2016

    acquisition - company. 235. Idera Pharmaceuticals/ Vivelix Pharmaceuticals. IMO-9200, antagonist of TLR 7, 8 and 9, for non-malignant GI disorders (p1) back ups.

  • Deal Watch November 2015 Deal Watch November 2015

    Option to license. 175. Idera Pharmaceuticals. GlaxoSmithKline. Licence, collaboration. Antisence platform for selected targets in renal disease.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • ImmuneXcite boosts senior leadership ImmuneXcite boosts senior leadership

    He is chairman of the board of Idera Pharmaceuticals and Juniper Pharmaceuticals and has previously worked at Sanofi-Aventis and Genzyme.

  • Idera Pharmaceuticals names new CEO Idera Pharmaceuticals names new CEO

    Idera Pharmaceuticals names new CEO. Vincent Milano was most recently CEO of Viropharma. ... Vincent Milano has been appointed CEO of Idera Pharmaceuticals almost one year after stepping down as CEO of ViroPharma.

  • Former Sanofi SVP to chair Idera Former Sanofi SVP to chair Idera

    Former Sanofi SVP to chair Idera. James Geraghty joins the firm with 20 years biotech experience from Genzyme. ... Idera specialises in developing toll-like receptors (TLRs) for autoimmune and inflammatory conditions and will benefit from Geraghty's

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics